María Lagarde

Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial

Federico Pulido, Esteban Ribera, María Lagarde et al. · Clinical Infectious Diseases · 2017 · 102 citations · Full text

Predictive factors for early mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia

Oriol Gasch, Mariana Camoez, M.Á. Domínguez et al. · Journal of Antimicrobial Chemotherapy · 2013 · 61 citations · Full text

Effects of Immunonutrition in Advanced Human Immunodeficiency Virus Disease: A Randomized Placebo-controlled Clinical Trial (Promaltia Study)

Sergio Serrano‐Villar, María Lagarde, Jorge F. Vázquez‐Castellanos et al. · Clinical Infectious Diseases · 2018 · 60 citations · Full text

Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus–Infected Patients With Nonalcoholic Fatty Liver Disease

Juan Macı́as, M.J. Mancebo, Dolores Merino et al. · Clinical Infectious Diseases · 2017 · 56 citations · Full text

Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events

Javier Martínez‐Sanz, Jorge Díaz-Álvarez, Marta Rosas Cancio-Suárez et al. · EBioMedicine · 2023 · 32 citations · Full text